SCHEMBL21295545

SCHEMBL21295545

O=C(Nc1ccccc1)Nc1ccc(Oc2ccccc2)c(OCC2COC2)c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NTRK1 P04629 2/20 0.54
NTRK3 Q16288 2/20 0.54
NTRK2 Q16620 2/20 0.54
MCHR1 Q99705 6/20 0.46
NPC1 O15118 2/20 0.45
RAB9A P51151 2/20 0.45
MAPT P10636 1/20 0.45
EPHX2 P34913 3/20 0.43
CA12 O43570 1/20 0.42
CA1 P00915 1/20 0.42
CA2 P00918 1/20 0.42
CA9 Q16790 1/20 0.42
MEN1 O00255 1/20 0.42
POLB P06746 1/20 0.42
KMT2A Q03164 1/20 0.42
IDH2 P48735 1/20 0.41
PDGFRA P16234 1/20 0.41
KDR P35968 1/20 0.41
P2RY1 P47900 1/20 0.41
EPHX1 P07099 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21295371 0.91 NTRK1 (0.52) NTRK1NTRK3NTRK2MCHR1KMT2A
SCHEMBL30744035 0.91 NTRK1 (0.52) NTRK1NTRK3NTRK2MCHR1KMT2A
SCHEMBL21295515 0.80 MCHR1 (0.59) MCHR1NPC1RAB9AMAPTCA12
SCHEMBL21295365 0.77 NTRK1 (0.56) NTRK1NTRK3NTRK2MCHR1NPC1
SCHEMBL21295386 0.77 MCHR1 (0.57) NTRK1NTRK3NTRK2MCHR1RAB9A
SCHEMBL21295383 0.76 NTRK1 (0.56) NTRK1NTRK3NTRK2MCHR1NPC1
SCHEMBL30744019 0.76 NTRK1 (0.56) NTRK1NTRK3NTRK2MCHR1NPC1
SCHEMBL21295536 0.76 KDR (0.61) MCHR1RAB9AMAPTMEN1KMT2A
SCHEMBL21295530 0.75 SMN1; SMN2 (0.53) MCHR1NPC1RAB9AMAPTCA12
SCHEMBL21295553 0.74 PDE4B (0.55) MCHR1NPC1RAB9AMAPTEPHX2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250214948-A1 TRIAZINE DERIVATIVES FOR TREATING DISEASES RELATING TO NEUROTROPHINS AlzeCure Pharma AB (SE) 2025-07-03 US disclosed
CN-111819172-B Triazine derivatives for the treatment of neurotrophin related diseases 阿泽克制药公司 2024-02-06 CN disclosed
EP-3759088-B1 TRIAZINE DERIVATIVES FOR TREATING DISEASES RELATING TO NEUROTROPHINS AlzeCure Pharma AB (SE) 2023-01-25 EP disclosed
EP-3759088-B1 TRIAZINE DERIVATIVES FOR TREATING DISEASES RELATING TO NEUROTROPHINS AlzeCure Pharma AB (SE) 2023-01-25 EP disclosed
US-20220306589-A1 TRIAZINE DERIVATIVES FOR TREATING DISEASES RELATING TO NEUROTROPHINS AlzeCure Pharma AB (SE) 2022-09-29 US disclosed
US-11352332-B2 Triazine derivatives for treating diseases relating to neurotrophins AlzeCure Pharma AB (SE) 2022-06-07 US disclosed
US-11352332-B2 Triazine derivatives for treating diseases relating to neurotrophins AlzeCure Pharma AB (SE) 2022-06-07 US disclosed
EP-3759088-A1 TRIAZINE DERIVATIVES FOR TREATING DISEASES RELATING TO NEUROTROPHINS Alzecure Pharma AB (SE) 2021-01-06 EP disclosed
US-20200399230-A1 TRIAZINE DERIVATIVES FOR TREATING DISEASES RELATING TO NEUROTROPHINS AlzeCure Pharma AB (SE) 2020-12-24 US disclosed
US-20200399230-A1 TRIAZINE DERIVATIVES FOR TREATING DISEASES RELATING TO NEUROTROPHINS AlzeCure Pharma AB (SE) 2020-12-24 US disclosed
CN-111819172-A Triazine derivatives for the treatment of neurotrophin-related disorders 阿泽克制药公司 2020-10-23 CN disclosed
WO-2019162702-A1 TRIAZINE DERIVATIVES FOR TREATING DISEASES RELATING TO NEUROTROPHINS AlzeCure Pharma AB (SE) 2019-08-29 WO disclosed
WO-2019162702-A1 TRIAZINE DERIVATIVES FOR TREATING DISEASES RELATING TO NEUROTROPHINS AlzeCure Pharma AB (SE) 2019-08-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220306589-A1 TRIAZINE DERIVATIVES FOR TREATING DISEASES RELATING TO NEUROTROPHINS NTRK2, BDNF, NGF NTRK1 15/4885NTRK3 5/4885NTRK2 1/4885
US-20250214948-A1 TRIAZINE DERIVATIVES FOR TREATING DISEASES RELATING TO NEUROTROPHINS NTRK2, BDNF, NGF NTRK1 15/4885NTRK3 5/4885NTRK2 1/4885
US-11352332-B2 Triazine derivatives for treating diseases relating to neurotrophins NTRK2, BDNF, NGF NTRK1 13/4885NTRK3 6/4885NTRK2 1/4885
US-20200399230-A1 TRIAZINE DERIVATIVES FOR TREATING DISEASES RELATING TO NEUROTROPHINS NTRK2, BDNF, NGF NTRK1 13/4885NTRK3 6/4885NTRK2 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.